0512 · HKEX · Hong Kong
grandpharm.comFinancials as of FY2025
Makes taurine and amino acids in its own factories, then turns them into approved drugs for respiratory, eye, and heart conditions — all under one roof.
What this company is and how it runs — written from structure, not news.
China Grand Pharmaceutical makes drugs for respiratory, ophthalmic, and cardiovascular conditions by running its own taurine and amino acid fermentation lines directly upstream of its manufacturing facilities — and because China's NMPA ties each drug approval to the exact facility where it is made, the fermentation supply, the factory, and the regulatory licence are a single locked unit that cannot be separated. A competitor wanting to replicate this position cannot simply build a fermentation plant and start selling, because the NMPA registrations naming those specific sites must be filed fresh, validated, and approved in a sequence that cannot be shortened by money or compressed by running multiple new drug categories at once. That same coupling is also the company's main vulnerability: if NMPA's ongoing harmonisation programme requires changes to the registered manufacturing sites, every drug approval tied to those facilities is suspended simultaneously until the upgraded site clears re-certification, meaning a single compliance event could pause sales across all three therapeutic areas at the same time.
How does this company make money?
Most revenue comes from selling finished pharmaceutical products — respiratory, ophthalmic, and cardiovascular drugs — to Chinese hospitals and to international distributors. The company also sells taurine and amino acids as chemicals to other manufacturers who use them as ingredients in their own products. A smaller share comes from licensing arrangements tied to collaborative research, including a partnership with the Sirtex Group.
What makes this company hard to replace?
Each drug the company sells has an NMPA registration that names this company's specific facility as the manufacturing site. A hospital or distributor that wanted to source that same drug from a different supplier would need to wait for a competitor to file a new registration under a different site and clear the full approval process. On top of that, Chinese hospital procurement systems run on multi-year contracts, so switching mid-contract is slow by design. The ongoing research collaboration with Wenzhou Medical University also involves shared intellectual property and clinical timelines that a new partner could not simply pick up.
What limits this company?
NMPA approvals name a specific facility and cannot be moved or stacked. Each new drug category — say, a new cardiovascular drug — requires its own clinical program and its own approval cycle, and those cycles cannot be run at the same time as each other. No matter how much fermentation or manufacturing capacity the company adds, the approval queue is always the bottleneck.
What does this company depend on?
The company cannot operate without NMPA manufacturing licenses for its pharmaceutical facilities, taurine and amino acid raw material sourcing to feed its fermentation lines, export licenses to sell into international markets, Chinese environmental permits that allow its wastewater treatment operations to run, and its strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University for ophthalmic drug development.
Who depends on this company?
Chinese hospital systems rely on it for domestically manufactured respiratory and cardiovascular medicines — if it stopped, those hospitals would face shortages with no direct replacement ready. The Eye Hospital of Wenzhou Medical University would lose its main partner for developing new eye drugs, including shared research and intellectual property. Asian pharmaceutical distributors that use this company's amino acid and taurine supply as inputs for their own manufacturing would have to find another source.
How does this company scale?
Adding fermentation tanks and chemical processing equipment is relatively straightforward and grows output efficiently. What does not scale easily is the approval side: every new therapeutic area needs its own NMPA clinical trial and registration program, those programs cannot be run in parallel across multiple new categories, and no amount of capital makes them faster.
What external forces can significantly affect this company?
China's ICH harmonization program keeps updating the standards that pharmaceutical factories must meet, which means facility upgrades are a recurring requirement. U.S.-China trade tensions create risk around export licenses and the sourcing of active pharmaceutical ingredients for international sales. Chinese environmental regulators are tightening the rules on wastewater discharge from pharmaceutical manufacturing, which puts ongoing pressure on the company's sewage treatment operations.
Where is this company structurally vulnerable?
China's NMPA is gradually aligning its rules with international standards through a program called ICH harmonization. If that program requires physical or process changes at this company's registered manufacturing sites, every drug whose approval names those sites would be suspended from sale at the same time — across respiratory, eye, and heart products simultaneously — until the upgraded facilities pass re-certification.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph